Numerous cytokine-targeting therapeutic modalities have been described as effective in alopecia areata such as JAK inhibitors, phosphodiesterase-4 inhibitor (apremilast), anti-IL-12/23 monoclonal antibody (ustekinumab), and anti-IL-17 monoclonal antibody (secukinumab) [8]. This evidence concerns the gene IL17A and alopecia areata.